United States End-Stage Renal Disease (ESRD) Drugs Market Report 2017

December 2017 | 97 pages | ID: UC85DEDAC3EEN
QYResearch

Abstracts

In this report, the United States End-Stage Renal Disease (ESRD) Drugs market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022.

Geographically, this report splits the United States market into seven regions:

• The West
• Southwest
• The Middle Atlantic
• New England
• The South
• The Midwest
• with sales (volume), revenue (value), market share and growth rate of End-Stage Renal Disease (ESRD) Drugs in these regions, from 2012 to 2022 (forecast).

United States End-Stage Renal Disease (ESRD) Drugs market competition by top manufacturers/players, with End-Stage Renal Disease (ESRD) Drugs sales volume, price, revenue (Million USD) and market share for each manufacturer/player; the top players including

• CTI BioPharma Corp
• Merck & Co Inc
• Novartis AG
• Prolong Pharmaceuticals LLC
• VESSL Therapeutics Ltd

On the basis of product, this report displays the production, revenue, price, market share and growth rate of each type, primarily split into

• Calcium Succinate
• Mk-3866
• Pacritinib
• Sanguinate
• Tesidolumab
• Others

On the basis on the end users/applications, this report focuses on the status and outlook for major applications/end users, sales volume, market share and growth rate for each application, including

• Hospital
• Clinic
• ICU
• Others

If you have any special requirements, please let us know and we will offer you the report as you want.

Contents

United States End-Stage Renal Disease (ESRD) Drugs Market Report 2017

1 END-STAGE RENAL DISEASE (ESRD) DRUGS OVERVIEW

1.1 Product Overview and Scope of End-Stage Renal Disease (ESRD) Drugs
1.2 Classification of End-Stage Renal Disease (ESRD) Drugs by Product Category
  1.2.1 United States End-Stage Renal Disease (ESRD) Drugs Market Size (Sales Volume) Comparison by Type (2012-2022)
  1.2.2 United States End-Stage Renal Disease (ESRD) Drugs Market Size (Sales Volume) Market Share by Type (Product Category) in 2016
  1.2.3 Calcium Succinate
  1.2.4 Mk-3866
  1.2.5 Pacritinib
  1.2.6 Sanguinate
  1.2.7 Tesidolumab
  1.2.8 Others
1.3 United States End-Stage Renal Disease (ESRD) Drugs Market by Application/End Users
  1.3.1 United States End-Stage Renal Disease (ESRD) Drugs Market Size (Consumption) and Market Share Comparison by Application (2012-2022)
  1.3.2 Hospital
  1.3.3 Clinic
  1.3.4 ICU
  1.3.5 Others
1.4 United States End-Stage Renal Disease (ESRD) Drugs Market by Region
  1.4.1 United States End-Stage Renal Disease (ESRD) Drugs Market Size (Value) Comparison by Region (2012-2022)
  1.4.2 The West End-Stage Renal Disease (ESRD) Drugs Status and Prospect (2012-2022)
  1.4.3 Southwest End-Stage Renal Disease (ESRD) Drugs Status and Prospect (2012-2022)
  1.4.4 The Middle Atlantic End-Stage Renal Disease (ESRD) Drugs Status and Prospect (2012-2022)
  1.4.5 New England End-Stage Renal Disease (ESRD) Drugs Status and Prospect (2012-2022)
  1.4.6 The South End-Stage Renal Disease (ESRD) Drugs Status and Prospect (2012-2022)
  1.4.7 The Midwest End-Stage Renal Disease (ESRD) Drugs Status and Prospect (2012-2022)
1.5 United States Market Size (Value and Volume) of End-Stage Renal Disease (ESRD) Drugs (2012-2022)
  1.5.1 United States End-Stage Renal Disease (ESRD) Drugs Sales and Growth Rate (2012-2022)
  1.5.2 United States End-Stage Renal Disease (ESRD) Drugs Revenue and Growth Rate (2012-2022)

2 UNITED STATES END-STAGE RENAL DISEASE (ESRD) DRUGS MARKET COMPETITION BY PLAYERS/SUPPLIERS

2.1 United States End-Stage Renal Disease (ESRD) Drugs Sales and Market Share of Key Players/Suppliers (2012-2017)
2.2 United States End-Stage Renal Disease (ESRD) Drugs Revenue and Share by Players/Suppliers (2012-2017)
2.3 United States End-Stage Renal Disease (ESRD) Drugs Average Price by Players/Suppliers (2012-2017)
2.4 United States End-Stage Renal Disease (ESRD) Drugs Market Competitive Situation and Trends
  2.4.1 United States End-Stage Renal Disease (ESRD) Drugs Market Concentration Rate
  2.4.2 United States End-Stage Renal Disease (ESRD) Drugs Market Share of Top 3 and Top 5 Players/Suppliers
  2.4.3 Mergers & Acquisitions, Expansion in United States Market
2.5 United States Players/Suppliers End-Stage Renal Disease (ESRD) Drugs Manufacturing Base Distribution, Sales Area, Product Type

3 UNITED STATES END-STAGE RENAL DISEASE (ESRD) DRUGS SALES (VOLUME) AND REVENUE (VALUE) BY REGION (2012-2017)

3.1 United States End-Stage Renal Disease (ESRD) Drugs Sales and Market Share by Region (2012-2017)
3.2 United States End-Stage Renal Disease (ESRD) Drugs Revenue and Market Share by Region (2012-2017)
3.3 United States End-Stage Renal Disease (ESRD) Drugs Price by Region (2012-2017)

4 UNITED STATES END-STAGE RENAL DISEASE (ESRD) DRUGS SALES (VOLUME) AND REVENUE (VALUE) BY TYPE (PRODUCT CATEGORY) (2012-2017)

4.1 United States End-Stage Renal Disease (ESRD) Drugs Sales and Market Share by Type (Product Category) (2012-2017)
4.2 United States End-Stage Renal Disease (ESRD) Drugs Revenue and Market Share by Type (2012-2017)
4.3 United States End-Stage Renal Disease (ESRD) Drugs Price by Type (2012-2017)
4.4 United States End-Stage Renal Disease (ESRD) Drugs Sales Growth Rate by Type (2012-2017)

5 UNITED STATES END-STAGE RENAL DISEASE (ESRD) DRUGS SALES (VOLUME) BY APPLICATION (2012-2017)

5.1 United States End-Stage Renal Disease (ESRD) Drugs Sales and Market Share by Application (2012-2017)
5.2 United States End-Stage Renal Disease (ESRD) Drugs Sales Growth Rate by Application (2012-2017)
5.3 Market Drivers and Opportunities

6 UNITED STATES END-STAGE RENAL DISEASE (ESRD) DRUGS PLAYERS/SUPPLIERS PROFILES AND SALES DATA

6.1 CTI BioPharma Corp
  6.1.1 Company Basic Information, Manufacturing Base and Competitors
  6.1.2 End-Stage Renal Disease (ESRD) Drugs Product Category, Application and Specification
    6.1.2.1 Product A
    6.1.2.2 Product B
  6.1.3 CTI BioPharma Corp End-Stage Renal Disease (ESRD) Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
  6.1.4 Main Business/Business Overview
6.2 Merck & Co Inc
  6.2.2 End-Stage Renal Disease (ESRD) Drugs Product Category, Application and Specification
    6.2.2.1 Product A
    6.2.2.2 Product B
  6.2.3 Merck & Co Inc End-Stage Renal Disease (ESRD) Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
  6.2.4 Main Business/Business Overview
6.3 Novartis AG
  6.3.2 End-Stage Renal Disease (ESRD) Drugs Product Category, Application and Specification
    6.3.2.1 Product A
    6.3.2.2 Product B
  6.3.3 Novartis AG End-Stage Renal Disease (ESRD) Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
  6.3.4 Main Business/Business Overview
6.4 Prolong Pharmaceuticals LLC
  6.4.2 End-Stage Renal Disease (ESRD) Drugs Product Category, Application and Specification
    6.4.2.1 Product A
    6.4.2.2 Product B
  6.4.3 Prolong Pharmaceuticals LLC End-Stage Renal Disease (ESRD) Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
  6.4.4 Main Business/Business Overview
6.5 VESSL Therapeutics Ltd
  6.5.2 End-Stage Renal Disease (ESRD) Drugs Product Category, Application and Specification
    6.5.2.1 Product A
    6.5.2.2 Product B
  6.5.3 VESSL Therapeutics Ltd End-Stage Renal Disease (ESRD) Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
  6.5.4 Main Business/Business Overview

7 END-STAGE RENAL DISEASE (ESRD) DRUGS MANUFACTURING COST ANALYSIS

7.1 End-Stage Renal Disease (ESRD) Drugs Key Raw Materials Analysis
  7.1.1 Key Raw Materials
  7.1.2 Price Trend of Key Raw Materials
  7.1.3 Key Suppliers of Raw Materials
  7.1.4 Market Concentration Rate of Raw Materials
7.2 Proportion of Manufacturing Cost Structure
  7.2.1 Raw Materials
  7.2.2 Labor Cost
  7.2.3 Manufacturing Expenses
7.3 Manufacturing Process Analysis of End-Stage Renal Disease (ESRD) Drugs

8 INDUSTRIAL CHAIN, SOURCING STRATEGY AND DOWNSTREAM BUYERS

8.1 End-Stage Renal Disease (ESRD) Drugs Industrial Chain Analysis
8.2 Upstream Raw Materials Sourcing
8.3 Raw Materials Sources of End-Stage Renal Disease (ESRD) Drugs Major Manufacturers in 2016
8.4 Downstream Buyers

9 MARKETING STRATEGY ANALYSIS, DISTRIBUTORS/TRADERS

9.1 Marketing Channel
  9.1.1 Direct Marketing
  9.1.2 Indirect Marketing
  9.1.3 Marketing Channel Development Trend
9.2 Market Positioning
  9.2.1 Pricing Strategy
  9.2.2 Brand Strategy
  9.2.3 Target Client
9.3 Distributors/Traders List

10 MARKET EFFECT FACTORS ANALYSIS

10.1 Technology Progress/Risk
  10.1.1 Substitutes Threat
  10.1.2 Technology Progress in Related Industry
10.2 Consumer Needs/Customer Preference Change
10.3 Economic/Political Environmental Change

11 UNITED STATES END-STAGE RENAL DISEASE (ESRD) DRUGS MARKET SIZE (VALUE AND VOLUME) FORECAST (2017-2022)

11.1 United States End-Stage Renal Disease (ESRD) Drugs Sales Volume, Revenue Forecast (2017-2022)
11.2 United States End-Stage Renal Disease (ESRD) Drugs Sales Volume Forecast by Type (2017-2022)
11.3 United States End-Stage Renal Disease (ESRD) Drugs Sales Volume Forecast by Application (2017-2022)
11.4 United States End-Stage Renal Disease (ESRD) Drugs Sales Volume Forecast by Region (2017-2022)

12 RESEARCH FINDINGS AND CONCLUSION

13 APPENDIX

13.1 Methodology/Research Approach
  13.1.1 Research Programs/Design
  13.1.2 Market Size Estimation
  13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
  13.2.1 Secondary Sources
  13.2.2 Primary Sources
13.3 Disclaimer


The report requires updating with new data and is sent in 2-3 business days after order is placed.

List Of Tables

LIST OF TABLES AND FIGURES

Figure Product Picture of End-Stage Renal Disease (ESRD) Drugs
Figure United States End-Stage Renal Disease (ESRD) Drugs Market Size (K Pcs) by Type (2012-2022)
Figure United States End-Stage Renal Disease (ESRD) Drugs Sales Volume Market Share by Type (Product Category) in 2016
Figure Calcium Succinate Product Picture
Figure Mk-3866 Product Picture
Figure Pacritinib Product Picture
Figure Sanguinate Product Picture
Figure Tesidolumab Product Picture
Figure Others Product Picture
Figure United States End-Stage Renal Disease (ESRD) Drugs Market Size (K Pcs) by Application (2012-2022)
Figure United States Sales Market Share of End-Stage Renal Disease (ESRD) Drugs by Application in 2016
Figure Hospital Examples
Table Key Downstream Customer in Hospital
Figure Clinic Examples
Table Key Downstream Customer in Clinic
Figure ICU Examples
Table Key Downstream Customer in ICU
Figure Others Examples
Table Key Downstream Customer in Others
Figure United States End-Stage Renal Disease (ESRD) Drugs Market Size (Million USD) by Region (2012-2022)
Figure The West End-Stage Renal Disease (ESRD) Drugs Revenue (Million USD) and Growth Rate (2012-2022)
Figure Southwest End-Stage Renal Disease (ESRD) Drugs Revenue (Million USD) and Growth Rate (2012-2022)
Figure The Middle Atlantic End-Stage Renal Disease (ESRD) Drugs Revenue (Million USD) and Growth Rate (2012-2022)
Figure New England End-Stage Renal Disease (ESRD) Drugs Revenue (Million USD) and Growth Rate (2012-2022)
Figure The South of US End-Stage Renal Disease (ESRD) Drugs Revenue (Million USD) and Growth Rate (2012-2022)
Figure The Midwest End-Stage Renal Disease (ESRD) Drugs Revenue (Million USD) and Growth Rate (2012-2022)
Figure United States End-Stage Renal Disease (ESRD) Drugs Sales (K Pcs) and Growth Rate (2012-2022)
Figure United States End-Stage Renal Disease (ESRD) Drugs Revenue (Million USD) and Growth Rate (2012-2022)
Figure United States End-Stage Renal Disease (ESRD) Drugs Market Major Players Product Sales Volume (K Pcs) (2012-2017)
Table United States End-Stage Renal Disease (ESRD) Drugs Sales (K Pcs) of Key Players/Suppliers (2012-2017)
Table United States End-Stage Renal Disease (ESRD) Drugs Sales Share by Players/Suppliers (2012-2017)
Figure 2016 United States End-Stage Renal Disease (ESRD) Drugs Sales Share by Players/Suppliers
Figure 2017 United States End-Stage Renal Disease (ESRD) Drugs Sales Share by Players/Suppliers
Figure United States End-Stage Renal Disease (ESRD) Drugs Market Major Players Product Revenue (Million USD) (2012-2017)
Table United States End-Stage Renal Disease (ESRD) Drugs Revenue (Million USD) by Players/Suppliers (2012-2017)
Table United States End-Stage Renal Disease (ESRD) Drugs Revenue Share by Players/Suppliers (2012-2017)
Figure 2016 United States End-Stage Renal Disease (ESRD) Drugs Revenue Share by Players/Suppliers
Figure 2017 United States End-Stage Renal Disease (ESRD) Drugs Revenue Share by Players/Suppliers
Table United States Market End-Stage Renal Disease (ESRD) Drugs Average Price (USD/Pcs) of Key Players/Suppliers (2012-2017)
Figure United States Market End-Stage Renal Disease (ESRD) Drugs Average Price (USD/Pcs) of Key Players/Suppliers in 2016
Figure United States End-Stage Renal Disease (ESRD) Drugs Market Share of Top 3 Players/Suppliers
Figure United States End-Stage Renal Disease (ESRD) Drugs Market Share of Top 5 Players/Suppliers
Table United States Players/Suppliers End-Stage Renal Disease (ESRD) Drugs Manufacturing Base Distribution and Sales Area
Table United States Players/Suppliers End-Stage Renal Disease (ESRD) Drugs Product Category
Table United States End-Stage Renal Disease (ESRD) Drugs Sales (K Pcs) by Region (2012-2017)
Table United States End-Stage Renal Disease (ESRD) Drugs Sales Share by Region (2012-2017)
Figure United States End-Stage Renal Disease (ESRD) Drugs Sales Share by Region (2012-2017)
Figure United States End-Stage Renal Disease (ESRD) Drugs Sales Market Share by Region in 2016
Table United States End-Stage Renal Disease (ESRD) Drugs Revenue (Million USD) and Market Share by Region (2012-2017)
Table United States End-Stage Renal Disease (ESRD) Drugs Revenue Share by Region (2012-2017)
Figure United States End-Stage Renal Disease (ESRD) Drugs Revenue Market Share by Region (2012-2017)
Figure United States End-Stage Renal Disease (ESRD) Drugs Revenue Market Share by Region in 2016
Table United States End-Stage Renal Disease (ESRD) Drugs Price (USD/Pcs) by Region (2012-2017)
Table United States End-Stage Renal Disease (ESRD) Drugs Sales (K Pcs) by Type (2012-2017)
Table United States End-Stage Renal Disease (ESRD) Drugs Sales Share by Type (2012-2017)
Figure United States End-Stage Renal Disease (ESRD) Drugs Sales Share by Type (2012-2017)
Figure United States End-Stage Renal Disease (ESRD) Drugs Sales Market Share by Type in 2016
Table United States End-Stage Renal Disease (ESRD) Drugs Revenue (Million USD) and Market Share by Type (2012-2017)
Table United States End-Stage Renal Disease (ESRD) Drugs Revenue Share by Type (2012-2017)
Figure Revenue Market Share of End-Stage Renal Disease (ESRD) Drugs by Type (2012-2017)
Figure Revenue Market Share of End-Stage Renal Disease (ESRD) Drugs by Type in 2016
Table United States End-Stage Renal Disease (ESRD) Drugs Price (USD/Pcs) by Types (2012-2017)
Figure United States End-Stage Renal Disease (ESRD) Drugs Sales Growth Rate by Type (2012-2017)
Table United States End-Stage Renal Disease (ESRD) Drugs Sales (K Pcs) by Application (2012-2017)
Table United States End-Stage Renal Disease (ESRD) Drugs Sales Market Share by Application (2012-2017)
Figure United States End-Stage Renal Disease (ESRD) Drugs Sales Market Share by Application (2012-2017)
Figure United States End-Stage Renal Disease (ESRD) Drugs Sales Market Share by Application in 2016
Table United States End-Stage Renal Disease (ESRD) Drugs Sales Growth Rate by Application (2012-2017)
Figure United States End-Stage Renal Disease (ESRD) Drugs Sales Growth Rate by Application (2012-2017)
Table CTI BioPharma Corp Basic Information List
Table CTI BioPharma Corp End-Stage Renal Disease (ESRD) Drugs Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2012-2017)
Figure CTI BioPharma Corp End-Stage Renal Disease (ESRD) Drugs Sales Growth Rate (2012-2017)
Figure CTI BioPharma Corp End-Stage Renal Disease (ESRD) Drugs Sales Market Share in United States (2012-2017)
Figure CTI BioPharma Corp End-Stage Renal Disease (ESRD) Drugs Revenue Market Share in United States (2012-2017)
Table Merck & Co Inc Basic Information List
Table Merck & Co Inc End-Stage Renal Disease (ESRD) Drugs Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2012-2017)
Figure Merck & Co Inc End-Stage Renal Disease (ESRD) Drugs Sales Growth Rate (2012-2017)
Figure Merck & Co Inc End-Stage Renal Disease (ESRD) Drugs Sales Market Share in United States (2012-2017)
Figure Merck & Co Inc End-Stage Renal Disease (ESRD) Drugs Revenue Market Share in United States (2012-2017)
Table Novartis AG Basic Information List
Table Novartis AG End-Stage Renal Disease (ESRD) Drugs Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2012-2017)
Figure Novartis AG End-Stage Renal Disease (ESRD) Drugs Sales Growth Rate (2012-2017)
Figure Novartis AG End-Stage Renal Disease (ESRD) Drugs Sales Market Share in United States (2012-2017)
Figure Novartis AG End-Stage Renal Disease (ESRD) Drugs Revenue Market Share in United States (2012-2017)
Table Prolong Pharmaceuticals LLC Basic Information List
Table Prolong Pharmaceuticals LLC End-Stage Renal Disease (ESRD) Drugs Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2012-2017)
Figure Prolong Pharmaceuticals LLC End-Stage Renal Disease (ESRD) Drugs Sales Growth Rate (2012-2017)
Figure Prolong Pharmaceuticals LLC End-Stage Renal Disease (ESRD) Drugs Sales Market Share in United States (2012-2017)
Figure Prolong Pharmaceuticals LLC End-Stage Renal Disease (ESRD) Drugs Revenue Market Share in United States (2012-2017)
Table VESSL Therapeutics Ltd Basic Information List
Table VESSL Therapeutics Ltd End-Stage Renal Disease (ESRD) Drugs Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2012-2017)
Figure VESSL Therapeutics Ltd End-Stage Renal Disease (ESRD) Drugs Sales Growth Rate (2012-2017)
Figure VESSL Therapeutics Ltd End-Stage Renal Disease (ESRD) Drugs Sales Market Share in United States (2012-2017)
Figure VESSL Therapeutics Ltd End-Stage Renal Disease (ESRD) Drugs Revenue Market Share in United States (2012-2017)
Table Production Base and Market Concentration Rate of Raw Material
Figure Price Trend of Key Raw Materials
Table Key Suppliers of Raw Materials
Figure Manufacturing Cost Structure of End-Stage Renal Disease (ESRD) Drugs
Figure Manufacturing Process Analysis of End-Stage Renal Disease (ESRD) Drugs
Figure End-Stage Renal Disease (ESRD) Drugs Industrial Chain Analysis
Table Raw Materials Sources of End-Stage Renal Disease (ESRD) Drugs Major Players/Suppliers in 2016
Table Major Buyers of End-Stage Renal Disease (ESRD) Drugs
Table Distributors/Traders List
Figure United States End-Stage Renal Disease (ESRD) Drugs Sales Volume (K Pcs) and Growth Rate Forecast (2017-2022)
Figure United States End-Stage Renal Disease (ESRD) Drugs Revenue (Million USD) and Growth Rate Forecast (2017-2022)
Figure United States End-Stage Renal Disease (ESRD) Drugs Price (USD/Pcs) Trend Forecast (2017-2022)
Table United States End-Stage Renal Disease (ESRD) Drugs Sales Volume (K Pcs) Forecast by Type (2017-2022)
Figure United States End-Stage Renal Disease (ESRD) Drugs Sales Volume (K Pcs) Forecast by Type (2017-2022)
Figure United States End-Stage Renal Disease (ESRD) Drugs Sales Volume (K Pcs) Forecast by Type in 2022
Table United States End-Stage Renal Disease (ESRD) Drugs Sales Volume (K Pcs) Forecast by Application (2017-2022)
Figure United States End-Stage Renal Disease (ESRD) Drugs Sales Volume (K Pcs) Forecast by Application (2017-2022)
Figure United States End-Stage Renal Disease (ESRD) Drugs Sales Volume (K Pcs) Forecast by Application in 2022
Table United States End-Stage Renal Disease (ESRD) Drugs Sales Volume (K Pcs) Forecast by Region (2017-2022)
Table United States End-Stage Renal Disease (ESRD) Drugs Sales Volume Share Forecast by Region (2017-2022)
Figure United States End-Stage Renal Disease (ESRD) Drugs Sales Volume Share Forecast by Region (2017-2022)
Figure United States End-Stage Renal Disease (ESRD) Drugs Sales Volume Share Forecast by Region in 2022
Table Research Programs/Design for This Report
Figure Bottom-up and Top-down Approaches for This Report
Figure Data Triangulation
Table Key Data Information from Secondary Sources
Table Key Data Information from Primary Sources